Genomic Valley Biotech Ltd vs DIVI S LABORATORIES LTD

A side-by-side comparison of Genomic Valley Biotech Ltd (539206) and DIVI S LABORATORIES LTD (DIVISLAB) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, DIVI S LABORATORIES LTD leads 539206 vs DIVISLAB on 10 of 14 metrics (1 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation13
  • Profitability22
  • Growth02
  • Size & financial health03
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

DIVISLAB takes 3/4

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

282.50
P/E ratio
96.86
2.20
P/B ratio
10.62
0.00%
Dividend yield
0.32%
₹1.18
EPS
₹96.73

Profitability

Even

How efficiently each company turns capital and sales into profit. Higher is better.

0.77%
Return on equity
16.50%
11.84%
Return on capital
22.00%
52.38%
EBITDA margin
33.00%
42.86%
Net margin
24.32%

Growth

DIVISLAB takes 2/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

-53.70%
Revenue CAGR (3Y)
10.78%
-64.13%
Profit CAGR (3Y)
12.10%

Size & financial health

DIVISLAB takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹9 Cr
Market cap
₹2.49L Cr
₹1 Cr
Revenue
₹10,560 Cr
₹0 Cr
Net profit
₹2,568 Cr
0.00
Debt / equity even
0.00
Genomic Valley Biotech Ltd
  • + ["Company is almost debt free."]
  • ["Though the company is reporting repeated profits, it is not paying out dividend", "The company has delivered a poor sales growth of 5.15% over past five years.", "Company has a low return on equity of 3.68% over last 3 years.", "Company has high debtors of 3,136 days.", "Promoter holding has decreased over last 3 years: -21.1%"]
DIVI S LABORATORIES LTD
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 39.0%"]
  • ["Stock is trading at 14.8 times its book value", "The company has delivered a poor sales growth of 8.67% over past five years."]
Genomic Valley Biotech Ltd full analysis DIVI S LABORATORIES LTD full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.